Leadless pacemakers may be an "attractive alternative" to transvenous devices when cardiologists treat older TAVR patients who experience conduction disorders.

Inspired by nature and funded by the European Research Council, a group of scientists and engineers thinks its new research could represent a significant breakthrough in TAVR care.

Care teams are always looking for new ways to limit the use of permanent pacemakers after TAVR. Could starting patients off with temporary devices be an answer? 

Edwards, an early investor when the company first launched in 2017, said the acquisition will ensure its TMVR platform reaches as many patients as possible. 

The self-expanding valve is not yet approved by the FDA, but care teams in other markets are reporting positive outcomes when patients go home the day after treatment. 

Patients with pulmonary hypertension are associated with increased short- and long-term risks of death following TAVR. Researchers emphasized the importance of learning as much as possible about this topic going forward. 

As one may expect, advances in TAVR and TMVR technologies are seen as key drivers of the market’s success.

Each valve type has its own benefits, researchers noted, but mechanical valves are associated with multiple long-term benefits compared to tissue/bioprosthetic valves.